A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

被引：10
|
作者：
Goto, Y. [1 ]
Okada, M. [2 ]
Kijima, T. [3 ]
Aoe, K. [4 ]
Kato, T. [5 ]
Fujimoto, N. [6 ]
Nakagawa, K. [7 ]
Takeda, Y. [8 ]
Hida, T. [9 ]
Kanai, K. [10 ]
Imamura, F. [11 ]
Oizumi, S. [12 ]
Takahashi, T. [13 ]
Takenoyama, M. [14 ]
Tanaka, H. [15 ]
Ohe, Y. [16 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hiroshima Univ, Hiroshima, Japan
[3] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
[4] Natl Hosp Org Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Okayama Rosai Hosp, Asbestos Study Ctr, Okayama, Japan
[7] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
[8] Natl Ctr Global Hlth & Med, Resp Med, Tokyo, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[10] Wakayama Med Univ, Wakayama, Japan
[11] Osaka Int Canc Inst, Dept Gen Thorac Surg, Osaka, Japan
[12] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapppro, Japan
[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[14] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[15] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan
[16] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
malignant pleural mesothelioma; Nivolumab; PD-1;
D O I：
10.1016/j.jtho.2017.09.634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 19.01
引用
收藏
页码：S1883 / S1883
页数：1
相关论文
共 50 条
  • [41] Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
    Qu, Yuan-Yuan
    Zhang, Hai-Liang
    Guo, Hongqian
    Luo, Hong
    Zou, Qing
    Xing, Nianzeng
    Xia, Shujie
    Sun, Zhongquan
    Zhang, Xuepei
    He, Chaohong
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Ding-Wei
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5838 - 5846
  • [42] Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
    Canova, S.
    Ceresoli, G. L.
    Grosso, F.
    Zucali, P. A.
    Gelsomino, F.
    Pasello, G.
    Mencoboni, M.
    Rulli, E.
    Galli, F.
    De Simone, I.
    Carlucci, L.
    De Angelis, A.
    Belletti, M.
    Bonomi, M.
    D'Aveni, A.
    Perrino, M.
    Bono, F.
    Cortinovis, D. L.
    ESMO OPEN, 2022, 7 (06)
  • [43] Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study
    Katsuya, Yuki
    Horinouchi, Hidehito
    Seto, Takashi
    Umemura, Shigeki
    Hosomi, Yukio
    Satouchi, Miyako
    Nishio, Makoto
    Kozuki, Toshiyuki
    Hida, Toyoaki
    Sukigara, Tamie
    Nakamura, Kenichi
    Kuchiba, Aya
    Ohe, Yuichiro
    EUROPEAN JOURNAL OF CANCER, 2019, 113 : 78 - 86
  • [44] Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
    Fennell, Dean A.
    King, Amy
    Mohammed, Seid
    Greystoke, Alastair
    Anthony, Sarah
    Poile, Charlotte
    Nusrat, Nada
    Scotland, Molly
    Bhundia, Vina
    Branson, Amy
    Brookes, Cassandra
    Darlison, Liz
    Dawson, Alan G.
    Gaba, Aarti
    Hutka, Margaret
    Morgan, Bruno
    Bajaj, Amrita
    Richards, Cathy
    Wells-Jordan, Peter
    Thomas, Anne
    LANCET ONCOLOGY, 2022, 23 (03) : 374 - 381
  • [45] Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial
    Bozorgmehr, Farastuk
    Christopoulos, Petros
    Chung, Inn
    Cvetkovic, Jelena
    Feisst, Manuel
    Krisam, Johannes
    Schneider, Marc A.
    Heussel, Claus Peter
    Kreuter, Michael
    Mueller, Daniel W.
    Thomas, Michael
    Rieken, Stefan
    BMC CANCER, 2022, 22 (01)
  • [46] A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
    Song, Yuqin
    Wu, Jianqiu
    Chen, Xinchuan
    Lin, Tongyu
    Cao, Junning
    Liu, Yanyan
    Zhao, Yaozhong
    Jin, Jie
    Huang, Haiwen
    Hu, Jianda
    Luo, Jun
    Zhang, Liling
    Xue, Hongwei
    Zhang, Qingyuan
    Wang, Weiwei
    Chen, Chunxia
    Feng, Jifeng
    Zhu, Jun
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7363 - 7369
  • [47] A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)
    Charbel Elias
    Youssef H. Zeidan
    Youssef Bouferraa
    Deborah Mukherji
    Sally Temraz
    Maya Charafeddine
    Monita Al Darazi
    Ali Shamseddine
    BMC Cancer, 22
  • [48] Phase II study of single-agent nivolumab in patients with myelofibrosis
    Abou Dalle, Iman
    Kantarjian, Hagop
    Daver, Naval
    Masarova, Lucia
    Pemmaraju, Naveen
    Bose, Prithivaj
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    ANNALS OF HEMATOLOGY, 2021, 100 (12) : 2957 - 2960
  • [49] A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)
    Elias, Charbel
    Zeidan, Youssef H.
    Bouferraa, Youssef
    Mukherji, Deborah
    Temraz, Sally
    Charafeddine, Maya
    Al Darazi, Monita
    Shamseddine, Ali
    BMC CANCER, 2022, 22 (01)
  • [50] Phase II study of single-agent nivolumab in patients with myelofibrosis
    Iman Abou Dalle
    Hagop Kantarjian
    Naval Daver
    Lucia Masarova
    Naveen Pemmaraju
    Prithivaj Bose
    Guillermo Garcia-Manero
    Srdan Verstovsek
    Annals of Hematology, 2021, 100 : 2957 - 2960
12345